High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data

Conclusion. Hypo-fractionated HDRT plus TKI therapy, is associated with a significant prolongation of disease control (overall PFS: 18.8 months), with manageable side effects. These real-world data support the use of local ablative approaches in oligo-progressive EGFR mut-NSCLC.

Source: In Vivo - June 29, 2020 Category: Research Authors: SANTARPIA, M., ALTAVILLA, G., BORSELLINO, N., GIRLANDO, A., MANCUSO, G., PERGOLIZZI, S., PIAZZA, D., PONTORIERO, A., VALERIO, M. R., GEBBIA, V. Tags: Clinical Studies Source Type: research